CN Patent

CN117700354A — 一种雷芬那辛的晶体形式及其制备方法

Assigned to Jiangsu Baiaoxinkang Pharmaceutical Technology Co ltd · Expires 2024-03-15 · 2y expired

What this patent protects

本发明提供一种雷芬那辛新游离碱晶型VI及其制备方法。所述雷芬那辛晶型VI具有较好的化学稳定性以及在比较高的湿度条件下较低的引湿性，其X‑射线粉末衍射图谱以2θ(°)表示，具有4.95±0.2°、7.46±0.2°、10.00±0.2°、12.93±0.2°、14.81±0.2°、17.63±0.2°、18.66±0.2°、19.74±0.2°、20.44±0.2°、21.34±0.2°、22.69±0.2°、25.34±0.2°的特征峰。

USPTO Abstract

本发明提供一种雷芬那辛新游离碱晶型VI及其制备方法。所述雷芬那辛晶型VI具有较好的化学稳定性以及在比较高的湿度条件下较低的引湿性，其X‑射线粉末衍射图谱以2θ(°)表示，具有4.95±0.2°、7.46±0.2°、10.00±0.2°、12.93±0.2°、14.81±0.2°、17.63±0.2°、18.66±0.2°、19.74±0.2°、20.44±0.2°、21.34±0.2°、22.69±0.2°、25.34±0.2°的特征峰。

Drugs covered by this patent

Patent Metadata

Patent number
CN117700354A
Jurisdiction
CN
Classification
—
Expires
2024-03-15
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Baiaoxinkang Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.